Clinical Trial Update: Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. [Phase 3]

View source ↗

Summary

A Phase 3 pilot trial evaluating grazoprevir plus elbasvir for 12 or 16 weeks in liver transplant recipients with hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Liver Transplantation, Hepatitis C | Phase 3 | Status: WITHDRAWN